小剂量螺内酯治疗顽固性高血压的系统评价被引量：9

下载PDF

导出

摘要目的系统评价小剂量螺内酯(安体舒通)治疗顽固性高血压(RH)的临床疗效和安全性。方法检索PubMed、中国期刊全文数据库等国内外数据库。以RH患者为研究对象;试验设计为病例对照试验;试验组为接受安体舒通+常规降压治疗的患者,对照组为接受常规降压治疗的患者。结果 7项病例对照研究共纳入1 020人,常规降压治疗基础上加用小剂量安体舒通可明显降低收缩压〔MD=-13.40,95%CI(-16.76,-10.03)〕、舒张压〔MD=-5.64,95%CI(-6.96,-4.33)〕,对血肌酐〔MD=1.38,95%CI(-0.19,2.94)〕水平无影响。结论 RH在使用常规降压药的基础上,加用小剂量的螺内酯可得到较好的降压效果,安全性较佳。

作者马宝新李宗清李花

机构地区滨州医学院附属医院

出处《中国老年学杂志》 CAS CSCD 北大核心 2013年第23期5801-5803,共3页 Chinese Journal of Gerontology

基金滨州医学院科研启动基金(No.BY2010KYQD05)

关键词安体舒通顽固性高血压 META分析

分类号 R541.4 [医药卫生—心血管疾病]

引文网络
相关文献

参考文献10

1Abolghasmi R, Taziki O. Efficacy of low dose spironolactone in chronic kidney disease with resistant hypertension [J] Saudi J Kidney Dis Transpl,2011 ,22 ( 1 ) :75-8.
2Alvarez-Alvarez B, Abad-Cardiel M, Fernandez-Cruz A, et al. Management of resistant arterial hypertension: role of spironolactone versus double blockade of the renin-angiotensin-aldosterone system [ J . J Hypertens,2010 ,28 ( 11 ) :2329-35.
3Rodilla E, Costa JA, Perez-Lahiguera F, et al. Spironolactone and doxazo- sin treatment in patients with resistant hypertension [J] Rev Esp Cardi- ol,2009,62(2) :158-66.
4Sharabi Y,Adler E, Shamis A, et al. Efficacy of add-on aldosterone recep- tor blocker in uncontrolled hypertension [ J ]. Am J Hypertens, 2006 , 19 (7) :750-5.
5Vaclavik J, Sedlak R, Plaehy M, et al. Addition of spironolactone in pa- tients with resistant arterial hypertension (ASPIRANT) :a randomized, double-blind, placebo-controlled trial [ J . Hypertension, 2011 , 57 ( 6 ) : 1069-75.
6刘庆,张新金.醛固酮拮抗剂治疗顽固性高血压的临床观察[J].中国实用医药,2011,6(23):156-157. 被引量：1
7张俊松,邓节喜,郭寿贵,陈劲松,阮发晖,窦燕,林庚海,吴轲.螺内酯治疗顽固性高血压的随机、单盲、对照试验[J].海南医学院学报,2012,18(6):788-790. 被引量：8
8Calhoun DA, Jones D, Textor S,et al. Resistant hypertension : diagnosis, e- valuation,and treatment. A scientific statement from the American heart association professional education committee of the counci! for high blood pressure research [ J . Hypertension,2008 , 51 ( 6 ) : 1403-19.
9de Souza F, Muxfeldt E, Fiszman R, et al. Efficacy of spironolactone ther- apy in patients with true resistant hypertension [J]. Hypertension, 2010, 55 ( 1 ) : 147-52.
10Engbaek M, Hjerrild M, Hallas J, et al. The effect of low-dose spirono- lactone on resistant hypertension[ J. J Am Soc Hypertens ,2010 ,4 ( 6 ) :290-4.

二级参考文献14

1梁峰,胡大一,吴明营.顽固性高血压治疗的现状与进展[J].中华高血压杂志,2010,18(7):631-634. 被引量：21
2Pimenta E, Calhoun DA, Oparil S. Mechanisms and treatment of resistant hypertension (J ) . Arq Bras Cardiol, 2007, 88 ( 6 ) : 604-613.
3Chapman N, Dobson J, Wilson S, et al. Effect of spironolact one on blood pressure in subjects with resistant hypertension, hyperten- sion, 2007,49(4) :839-845.
4Moser M, Setaro JF. Resistant or difficult-to-control hypertension[J]. N Engl J Med,2006,355 : 385-392.
5Jodi H, Marcel R, Swapnil H, et al. Spironolactone for difficult to control hypertension in chronic kidney dis- ease: an analysis of safety and efficacy[J].J Am Socie- ty Hypertension, 2010, 4: 295-301.
6Va'clavik J, Sedlalk R, Plachy' M, et al. Addition of Spironolaetone in Patients with Resistant Arterial Hy- pertension (ASPIRANT) : A randomized,double-blind, placebo-controlled trial [J].Hypertension, 2011, 57: 1069-1075.
7de Souza F, Muxfeldt E, Fiszman R, et al. Efficacy of spironolactone therapy in patients with true resistant hypertension[J].Hypertension, 2010,55 : 147-152.
8Saha C, Eckert GJ, Ambrosius WT, et al. Improve- ment in blood pressure with inhibition of the epithelial sodium channel in blacks with hypertension[J]. Hyper- tension,2005,46 : 481-487.
9London GM. Role of arterial wall properties in the pathogenesis of systolic hypertension[J]. Am J Hyper- tens, 2005,18 : 19S-22S.
10Alvarez-Alvarez B, Abad-Cardiel M, Fernandez-Cruz A, et al. Management o5 resistant arterial hyperten- sion., role of spironolactone versus double blockade of the renin-angiotensin-aldosterone system[J]. J Hyper-tens, 2010,28:2329-2335.